This article is more than 5 years old. Information may no longer be current.

Biem Pharmaceuticals to commercialize InSite's AzaSite in Turkey

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ALAMEDA, Calif. — InSite Vision has signed a licensing and distribution agreement with Biem Pharmaceuticals regarding InSite's AzaSite ophthalmic solution for treating bacterial conjunctivitis, InSite announced in a press release.

Under the terms of the agreement, InSite will grant Biem exclusive rights to commercialize AzaSite (azithromycin 1%) in Turkey. In addition, an option to distribute AzaSite to Biem's export markets will be considered at a later date, the release said.

Also under the agreement, Biem will be responsible for securing regulatory approval of AzaSite for the Turkish market. In exchange, Biem will pay all costs associated with registering the product in Turkey and will provide a double-digit royalty to InSite on net sales of AzaSite pending regulatory approval.

InSite will be responsible for providing the manufactured product, the release said.